Question

Select a company or organization whose fairness or ethics is currently being scrutinized in the news or in social media. Provide enough background information about your selected company to convey its size and prominence in society, and then explain in detail the alleged fairness and ethics violations. Conclude your paper by choosing to support the allegations or refute them, and explain your reasoning based on what you have learned. In your discussion, be sure to include the information below.

• Summarize the concept of fairness as it relates to decisions.
• Explain how personal and business ethics can be subconsciously overridden in decision-making. Does your selected business exemplify this?
• Describe how the company could improve its image regarding fairness and ethics in decision-making.

Your paper must be a minimum of three pages in length, and it should contain at least two academic references (one maybe the textbook). Please use APA formatting and citations.

Answer 1

ONCOFREEZE AI

Patient respiratory motion during a PET/CT exam compromises image quality and could negatively impact patient outcomes. The standard solution for respiratory motion management is not performed during every PET/CT exam because it requires a longer scan time as well as a respiratory belt – which is awkward, time-consuming, and unpopular with patients. OncoFreeze AI uses ALPHA technology and algorithms to allow acquisition of PET/CT images that are virtually free of respiratory motion utilizing 100 percent of the acquired PET counts, with no additional time added to the exam and no respiratory belt.

MULTIPARAMETRIC PET SUITE AI

In PET/CT, standard uptake values (SUVs) alone may not be ideal for determining disease status, as patient diet and weight fluctuations result in variable SUV values. Multiparametric PET provides those coveted absolute numbers, but the exam can be cumbersome, and the requirement of arterial blood sampling can cause pain and put patients at risk. Multiparametric PET Suite AI offers a fully automated workflow that extracts the arterial input function automatically from acquired PET/CT images, eliminating the unnecessary pain and risk associated with arterial lines and sampling. In addition to the standard SUV image, Multiparametric PET Suite AI provides clinical information for the patient report in the form of metabolic rate and distribution volume, further expanding precision medicine.

“The addition of AIDAN to the Siemens Healthineers Biograph PET/CT portfolio represents a significant advancement in AI application at the scanner level,” said John Khoury, vice president of the Molecular Imaging business at Siemens Healthineers North America. “With AIDAN, we use robust learning technology to accelerate and improve the planning, acquisition, and interpretation of PET/CT.”